162. 類天疱瘡（後天性表皮水疱症を含む。） Pemphigoid Clinical trials / Disease details
臨床試験数 : 83 / 薬物数 : 128 - (DrugBank : 51) / 標的遺伝子数 : 33 - 標的パスウェイ数 : 142
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04744623 (ClinicalTrials.gov) | September 30, 2020 | 2/2/2021 | Clinical Evaluation of New Treatment Strategy of Mucous Membrane Pemphigoid Using Large Dose of Prednisolone Plus Intra-lesional of Triamcinolone Acetonide Followed by Combination of Mycophenolate Mofetil, Dapsone and Low Dose Prednisolone | Clinical Evaluation of New Treatment Strategy of Mucous Membrane Pemphigoid Using Large Dose of Prednisolone Plus Intra-lesional of Triamcinolone Acetonide Followed by Combination of Mycophenolate Mofetil, Dapsone and Low Dose Prednisolone | Benign Mucous Membrane Pemphigoid | Drug: large dose of prednisolone plus intra-lesional of Triamcinolone Acetonide followed the systemic combination of mycophenolate mofetil (MMF), dapsone and low dose prednisolone in treatment of MMP | Tanta University | NULL | Active, not recruiting | 40 Years | 60 Years | All | 10 | Phase 2/Phase 3 | Egypt |
| 2 | EUCTR2007-006658-24-DE (EUCTR) | 16/12/2009 | 08/09/2009 | A randomised controlled trial to compare the safety and effectiveness of doxycycline (200 mg/day) with prednisolone (0.5 mg/kg/day) for initial treatment of bullous pemphigoid - Bullous Pemphigoid Steroids & Tetracyclines Study | A randomised controlled trial to compare the safety and effectiveness of doxycycline (200 mg/day) with prednisolone (0.5 mg/kg/day) for initial treatment of bullous pemphigoid - Bullous Pemphigoid Steroids & Tetracyclines Study | BP is a serious condition with a significant associated morbidity and mortality rate. Widespread tense and haemorrhagic blisters, skin erosions and severe itching cause patients a great deal of distress and pain. It occurs mainly in the elderly. The mortality rate in treated patients is estimated to range from 20% - 40% at one year. MedDRA version: 9.1;Level: LLT;Classification code 10006568;Term: Bullous pemphigoid NOS MedDRA version: 9.1;Classification code 10006567;Term: Bullous pemphigoid | Product Name: prednisolone INN or Proposed INN: prednisolone Product Name: doxycycline INN or Proposed INN: doxycycline | Universitätsklinikum Schleswig-Holstein | NULL | Not Recruiting | Female: yes Male: yes | 256 | Phase 4 | Germany;United Kingdom | ||
| 3 | EUCTR2007-006658-24-GB (EUCTR) | 05/03/2009 | 22/10/2008 | A randomised controlled trial to compare the safety and effectiveness of doxycycline (200 mg/day) with prednisolone (0.5 mg/kg/day) for initial treatment of bullous pemphigoid - Bullous Pemphigoid Steroids & Tetracyclines Study | A randomised controlled trial to compare the safety and effectiveness of doxycycline (200 mg/day) with prednisolone (0.5 mg/kg/day) for initial treatment of bullous pemphigoid - Bullous Pemphigoid Steroids & Tetracyclines Study | BP is a serious condition with a significant associated morbidity and mortality rate. Widespread tense and haemorrhagic blisters, skin erosions and severe itching cause patients a great deal of distress and pain. It occurs mainly in the elderly. The mortality rate in treated patients is estimated to range from 20% - 40% at one year. MedDRA version: 14.0;Level: LLT;Classification code 10006568;Term: Bullous pemphigoid NOS;System Organ Class: 10040785 - Skin and subcutaneous tissue disorders MedDRA version: 14.0;Classification code 10006567;Term: Bullous pemphigoid;System Organ Class: 10040785 - Skin and subcutaneous tissue disorders | Product Name: prednisolone INN or Proposed INN: prednisolone Product Name: doxycycline INN or Proposed INN: doxycycline Product Name: prednisolone INN or Proposed INN: prednisolone Product Name: prednisolone INN or Proposed INN: prednisolone Product Name: doxycycline INN or Proposed INN: doxycycline | University of Nottingham | NULL | Not Recruiting | Female: yes Male: yes | 256 | Human pharmacology (Phase 1): Therapeutic exploratory (Phase 2): Therapeutic confirmatory - (Phase 3): Therapeutic use (Phase 4): yes | Germany;United Kingdom |